Search

[12] Requiring GMP certification for medical cannabis products could, however, result in a 2-tier regulatory system (with GPP and GMP certification required for recreational and medical cannabis products, respectively), and some producers may elect to exit the medical cannabis market. Health Canada also maintains a system for reporting adverse events associated with cannabis products on its Canada Vigilance website.[9] Licensed cannabis producers are required to report serious adverse events associated with the use of their products, but it is not mandatory for health care providers to do so. Children with chronic debilitating illness and pain are increasingly using cannabis for medical purposes, particularly when conventional treatment options have limited benefit or substantial adverse effects. [Extracted from the article]

The article discusses the aspects to consider for clinical trials to study the use of cannabinoids for Canadian children with neurologic disorders. Topics mentioned include the need for clinical trials on the use of cannabinoids in pediatric patients to determine its safety and effectiveness and to guide in dosing and the requirements for clinical trial design considerations, such as engagement with families, innovative methods, and multisite collaboration.